EB-002

	EB-002 EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders. It is taken by mouth. The drug is under development by Enveric Biosciences. As of November 2024, it is in the preclinical research stage of development. In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62million. Its exact chemical structure does not yet appear to have been disclosed. See also * List of investigational hallucinogens and entactogens This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmenta ... * RE-109 * RE-104 * MSP-1014 Ref ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	MSP-1014 MSP-1014 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder, other depressive disorders, and anxiety disorders.Araujo JA, Higgins GA, de Lannoy IA, Dean I, Atkinson J, Lanthier J, Slassi M. (2022 November 13). 147.05 / JJ5 - The preclinical safety, behavioural and pharmacokinetics properties of MSP-1014, a novel prodrug of psilocin. Neuroscience 2022. https://www.abstractsonline.com/pp8/#!/10619/presentation/70912 It is a prodrug of psilocin similarly to psilocybin, and hence acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. The drug is under development by Mindset Pharma and Otsuka America Pharmaceutical. As of January 2024, it is in phase 2 clinical trials for major depressive disorder and is in the preclinical stage of development for anxiety disorders and other depressive disorders. The chemical structure of MSP-1014 does not yet seem to have been disclosed. However, Mindse ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	Experimental Hallucinogens This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.'' The list also includes non-hallucinogenic drugs related to hallucinogens, such as non-hallucinogenic serotonin 5-HT2A receptor agonists and non-hallucinogenic ketamine analogues. Cannabinoids, or cannabinoid receptor modulators, are not included in this list. Many of the indications are not for continuous medication therapy but rather are for medication-assisted psychotherapy or short-term use only. The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications. This list was last comprehensively updated in October 2024. It is likely to become outdated with time. Under development Preregistration * Midomafetamine (MDMA ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	RE-104 RE104, formerly known as FT-104, and as 4-glutaryloxy-''N'',''N''-diisopropyltryptamine (4-HO-DiPT ''O''-glutarate or 4-GO-DiPT), is an investigational drug product being developed by the pharmaceutical company Reunion Neuroscience. RE104 a prodrug ester of a synthetic psychedelic 4-hydroxytryptamine, 4-HO-DiPT. It is one of a number of related psychedelic derivatives being developed as pharmaceuticals to treat mood disorders. RE104 is in human clinical trials as a possible treatment for postpartum depression and treatment-resistant depression. As of 2024, RE104 entered a Phase II clinical trial for post-partum depression. Pharmacology RE104 is a prodrug that is converted into the psychedelic tryptamine 4-HO-DiPT upon administration. 4-OH-DiPT s chemically related to the neurotransmitter serotonin and acts as a non-selective agonist of the serotonin receptors. 4-OH-DiPT acts as an agonist on the serotonin 2A receptor (Ki 120 nM). Activation of one serotonin receptor, th ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]
	RE-109 ''O''-Glutarylpsilocin (developmental code name RE109), also known as 4-glutaryloxy-''N'',''N''-dimethyltryptamine (4-HO-DMT ''O''-glutarate) is a serotonergic psychedelic of the tryptamine family. It acts as a prodrug of psilocin (4-HO-DMT) similarly to other psilocin prodrugs like 4-AcO-DMT, 4-PrO-DMT, and psilocybin (4-PO-DMT). The drug is bond cleavage, cleaved into psilocin by non-specific esterases. ''O''-Glutarylpsilocin was first described in the scientific literature in 2024. It has been patented by Reunion Neuroscience. A related drug, RE-104 (4-GO-DiPT), a prodrug A prodrug is a pharmacologically inactive medication or compound that, after intake, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Instead of administering a drug directly, a corresponding prodrug can be ... of 4-HO-DiPT, is being developed for potential medical use. See also * List of investigational hallucinogens and entactogens * EB-002 * MSP-1014 References E ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]